BRAFV600E Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer
- 456 Downloads
The BRAF V600E mutation is a recognised molecular marker in papillary thyroid cancer (PTC), reported incidence from 30 to 80 %. BRAFV600E aberrantly activates the MAPK pathway, a central regulator of cell growth and proliferation. Previous studies have reported conflicting data regarding the impact of BRAFV600E on clinicopathological features of PTC. The study aims to determine whether BRAFV600E is useful as a prognostic biomarker in PTC.
A cohort study of patients undergoing surgery for PTC was undertaken. The primary outcome measure was disease-free survival. Secondary outcome measures were tumour size, nodal positivity and radioactive iodine ablation rate. All cases were re-examined to confirm PTC. Immunohistochemistry for BRAFV600E was performed on tissue microarrays. A single endocrine pathologist, blinded to clinicopathological data, interpreted staining.
496 patients with PTC were included, and 309 (62 %) were BRAFV600E positive. Tumour size was similar for BRAFV600E-positive and -negative tumours (21.3 vs. 23.2 mm, p = 0.23). BRAFV600E-positive patients were significantly older at first operation (mean age 45 versus 49 years, p = 0.003). BRAFV600E-positive PTCs had a higher rate of disease recurrence (12.9 vs. 5.6 %, p = 0.004), lymph node metastasis (44 vs. 29.4 %, p = 0.004) and extra-thyroidal extension (44 vs. 22 %, p < 0.001). Five-year disease-free survival was 89.6 % for BRAFV600E positive and 96.3 % for negative tumours, p < 0.001. There was no difference between groups for vascular invasion or multifocality. The mean follow-up was 57 months for both groups.
BRAFV600E in PTC predicts an increased risk of lymph node metastasis, extra-thyroidal extension and reduced disease-free survival. It is an additional useful prognostic biomarker.
KeywordsThyroid Cancer Papillary Thyroid Carcinoma Papillary Thyroid Cancer Vemurafenib Cervical Lymph Node Metastasis
- 16.Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88(11):5399–5404CrossRefPubMedGoogle Scholar
- 21.Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C et al (2012) The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97(12):4390–4398CrossRefPubMedGoogle Scholar
- 23.Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P (2006) The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane. Endocr Relat Cancer 13(1):257–269CrossRefPubMedGoogle Scholar
- 26.Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R (2013) Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol: 965212Google Scholar
- 33.Henke LE, Pfeifer JD, Ma C, Perkins SM, DeWees T, El-Mofty S, et al (2015) BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma. Cancer MedGoogle Scholar